Leong et al. developed a specific ADC that effectively inhibits breast cancer growth [117], while Smit et al. found that ovarian cancer regression can be achieved by utilizing B7-H4–targeting CAR therapy, despite being currently limited by off-target and off-tumor toxicity [112,118]. This evidence concerns the gene VTCN1 and breast carcinoma.